News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AviaraDx, Inc. Appoints Judd Jessup, Former CEO Of US LABS, To Its Board Of Directors


7/28/2006 11:18:21 AM

CARLSBAD, Calif., July 28 /PRNewswire/ -- AviaraDx, Inc., a molecular cancer profiling company enabling personalized medicine in oncology, announced today the appointment of Judd Jessup to its Board of Directors.

Mr. Jessup brings to AviaraDx over 30 years of experience in the management of healthcare companies. Most recently, Mr. Jessup served as CEO of US Labs, which was acquired by Laboratory Corporation of America in 2005. Prior to US Labs, Mr. Jessup was President of the HMO Division of FHP International and President of TakeCare, Inc., a 750,000 member, publicly- traded HMO. Mr. Jessup currently serves on the Boards of Directors of XIFIN, Inc., AccentCare, Inc., NovaMed, Inc. and Corvel Corporation.

"We are truly excited that Judd has joined our Board," said Antonius Schuh, Ph.D., Chief Executive Officer of AviaraDx, Inc. "His extensive experience as a seasoned Board member of several public companies and direct experience as a CEO in the promising space of laboratory diagnostics will complement our existing Board as we move closer towards launching our own CLIA certified laboratory operation."

"AviaraDx is one of the industry leaders driving personalized medicine through innovative molecular diagnostic technologies with significant clinical relevance. I'm excited to join the company's Board of Directors at a time when patients begin to benefit from diagnostic tests enabled by the company's groundbreaking technologies," said Mr. Jessup.

About AviaraDx, Inc.

AviaraDx, Inc., is focused on developing and commercializing molecular diagnostic technologies for personalized medicine in cancer treatment. The company is targeting the oncology market with three first-in-class molecular cancer profiling technologies: Molecular Cancer Identification (MCID), Breast Cancer Profiling (BCP) and Drug Response Profiling (DRP). To date, AviaraDx has licensed its MCID and BCP technologies for specific clinical indications to Quest Diagnostics, Laboratory Corporation of America and Agendia BV. The Company anticipates to operate its own CLIA certified diagnostic laboratory operations in early 2007 to complement its current partner offerings. AviaraDx, formerly Arcturus Bioscience, has recently relocated its headquarters from Mountain View, California, to Carlsbad, California. Please visit the AviaraDx website at http://www.aviaradx.com for more information.

Contact: Steve Zaniboni Chief Financial Officer (760) 579-0514

AviaraDx, Inc.

CONTACT: Steve Zaniboni, Chief Financial Officer of AviaraDx, Inc.,+1-760-579-0514


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES